FGF-1 stimulates the development of several types of cancers, including bladder cancer, hepatocellular carcinoma, pancreatic cancer and breast cancer 11–13, which suggests that FGF-1 signalling is a potential target for cancer therapy. Here, FGF1 is linked to urinary bladder cancer.